Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

Selexis announces strategic agreement with Zyngenia

Selexis SA announced today a strategic agreement with Zyngenia Inc. under which Selexis will utilize its' industry-leading SURE Cell Line Development Platform to generate production cell lines for Zyngenia's lead Zybody therapeutic programs.

15 Nov 2010

Domainex, Sigma-Aldrich enter collaboration to study epigenetic proteins

Domainex Ltd., the Contract Research Organization committed to excellence in drug discovery, today announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics. These epigenetic proteins regulate DNA expression and can be critical to cancer and stem cell biology research. Funding from the UK Government-backed Technology Strategy Board will support this work.

15 Nov 2010

Astrimmune, London Genetics enter collaboration to plan biomarker identification program

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme.

14 Nov 2010

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

CytomX awarded $488,000 as grant under QTDP Program

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Glycotope GmbH to present advances in GlycoExpress technology at BIO-Europe

Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress technology of novel human cell lines during the upcoming BIO-Europe in Munich.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

PharmAthene third quarter revenue decreases from $6.8 million to $6.2 million

PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2010.

11 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Halpin Foundation-ASN grant advances research in membranous nephropathy

The Halpin Foundation and the American Society of Nephrology (ASN) proudly highlight the research advances in membranous nephropathy made possible by The Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant.

11 Nov 2010

Portugal research groups awarded Gates Foundation grants

Two research groups in Portugal are to receive Grand Challenges Exploration Grants from the Bill & Melinda Gates Foundation. One of these research teams is led by Miguel Prud-ncio, at the Instituto de Medicina Molecular (IMM), and the other by Miguel Soares, at the Instituto Gulbenkian de Ci-ncia (IGC) together with Henrique Silveira, at the Instituto de Higiene e Medicina Tropical (IHMT).

11 Nov 2010

New approach to sneak nerve-protective drug erythropoietin into blood-brain barrier

Scientists are reporting development of a long-sought method with the potential for getting medication through a biological barrier that surrounds the brain, where it may limit the brain damage caused by stroke. Their approach for sneaking the nerve-protective drug erythropoietin into the brain is medicine's version of the Trojan Horse ploy straight out of ancient Greek legend.

11 Nov 2010

Scientists identify new way to drive dendritic cells from blood monocytes

Dendritic cells, known to be the prime movers of the body's immune response, are still notoriously difficult to study in humans. Samples, which come primarily from bone marrow or lymphoid tissue, are simply too difficult to obtain. But new research at Rockefeller University has shown scientists a way to study "authentic" dendritic cells from mouse monocytes, which are abundant in the blood, a much more accessible source in humans.

11 Nov 2010

SRU Biosystems announces launch of annual Label-free Technology Award

SRU Biosystems, a leader in label-free technologies, announced today the launch of its annual Label-free Technology Award. This year the company will award its newest label-free BIND SCANNER to an academic or non-profit laboratory to support innovative scientific and drug discovery research.

11 Nov 2010

Micromet to offer shares of common stock

Micromet, Inc. announced today that it intends, subject to market and other conditions, to offer shares of its common stock pursuant to an underwriting agreement with Piper Jaffray & Co. Piper Jaffray is acting as sole underwriter for this offering.

10 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Antibody News and Research

Further Reading

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Selexis announces strategic agreement with Zyngenia

Domainex, Sigma-Aldrich enter collaboration to study epigenetic proteins

Astrimmune, London Genetics enter collaboration to plan biomarker identification program

Amorfix second quarter net loss decreases to $25,728

CytomX awarded $488,000 as grant under QTDP Program

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Glycotope GmbH to present advances in GlycoExpress technology at BIO-Europe

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

PharmAthene third quarter revenue decreases from $6.8 million to $6.2 million

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Halpin Foundation-ASN grant advances research in membranous nephropathy

Portugal research groups awarded Gates Foundation grants

New approach to sneak nerve-protective drug erythropoietin into blood-brain barrier

Scientists identify new way to drive dendritic cells from blood monocytes

SRU Biosystems announces launch of annual Label-free Technology Award

Micromet to offer shares of common stock

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News